CTNNA1

Across TCGA pan-cancer cohorts, CTNNA1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTNNA1 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTNNA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTNNA1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where CTNNA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.567	0.297	<.001	46	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.805	.010	19	view →
HNSC	DFS	Median	II,III,IV	0.985	0.886	.005	9	view →
LUAD	DFS	Quartile	All	0.802	0.953	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTNNA1–PDAC (DFS)

Open the PDAC breakdown →